Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:CYTK NASDAQ:PRAX NASDAQ:RLAY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$101.53-3.2%$116.81$5.69▼$148.83$8.36B0.692.64 million shs2.62 million shsCYTKCytokinetics$71.48-1.1%$69.97$31.99▼$80.20$9.00B0.422.13 million shs1.61 million shsPRAXPraxis Precision Medicines$254.00-4.1%$325.52$37.19▼$366.52$7.38B2.71445,340 shs570,041 shsRLAYRelay Therapeutics$13.52-7.0%$13.52$2.98▼$17.47$2.79B1.754.74 million shs6.07 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+16.39%-18.97%-15.23%-4.02%+1,201.86%CYTKCytokinetics+2.23%-5.88%-6.23%+19.67%+123.05%PRAXPraxis Precision Medicines-5.08%-24.92%-20.57%-14.79%+539.96%RLAYRelay Therapeutics-4.97%+4.60%+11.85%+47.02%+350.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$101.53-3.2%$116.81$5.69▼$148.83$8.36B0.692.64 million shs2.62 million shsCYTKCytokinetics$71.48-1.1%$69.97$31.99▼$80.20$9.00B0.422.13 million shs1.61 million shsPRAXPraxis Precision Medicines$254.00-4.1%$325.52$37.19▼$366.52$7.38B2.71445,340 shs570,041 shsRLAYRelay Therapeutics$13.52-7.0%$13.52$2.98▼$17.47$2.79B1.754.74 million shs6.07 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+16.39%-18.97%-15.23%-4.02%+1,201.86%CYTKCytokinetics+2.23%-5.88%-6.23%+19.67%+123.05%PRAXPraxis Precision Medicines-5.08%-24.92%-20.57%-14.79%+539.96%RLAYRelay Therapeutics-4.97%+4.60%+11.85%+47.02%+350.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.73Moderate Buy$130.0828.12% UpsideCYTKCytokinetics 2.86Moderate Buy$99.3038.92% UpsidePRAXPraxis Precision Medicines 2.95Moderate Buy$572.72125.48% UpsideRLAYRelay Therapeutics 3.00Buy$23.3072.34% UpsideCurrent Analyst Ratings BreakdownLatest RLAY, ABVX, PRAX, and CYTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026ABVXAbivax Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$136.006/3/2026ABVXAbivax Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/2/2026PRAXPraxis Precision Medicines TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/2/2026PRAXPraxis Precision Medicines Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$715.00 ➝ $616.006/2/2026ABVXAbivax Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$140.00 ➝ $135.006/2/2026ABVXAbivax Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$145.00 ➝ $132.006/2/2026PRAXPraxis Precision Medicines OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$750.00 ➝ $650.006/2/2026ABVXAbivax CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/2/2026PRAXPraxis Precision Medicines BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$843.00 ➝ $810.006/2/2026PRAXPraxis Precision Medicines Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$420.00 ➝ $374.006/2/2026ABVXAbivax Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$160.00 ➝ $90.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$6.57 per shareN/ACYTKCytokinetics$88.04M101.03N/AN/A($5.39) per share-13.26PRAXPraxis Precision Medicines$8.55M828.25N/AN/A$34.85 per share7.29RLAYRelay Therapeutics$15.35M168.75N/AN/A$3.27 per share4.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%N/ACYTKCytokinetics-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%8/6/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)RLAYRelay Therapeutics-$276.48M-$1.57N/AN/AN/AN/A-43.94%-40.11%8/6/2026 (Estimated)Latest RLAY, ABVX, PRAX, and CYTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2026Q1 2026ABVXAbivax-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million5/5/2026Q1 2026RLAYRelay Therapeutics-$0.35-$0.41-$0.06-$0.41$5.58 million$3.00 million3/23/2026Q4 2025ABVXAbivax-$2.24-$1.20+$1.04-$1.20$1.80 million$0.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A8.258.25CYTKCytokineticsN/A4.214.21PRAXPraxis Precision MedicinesN/A15.8815.88RLAYRelay TherapeuticsN/A22.1322.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%CYTKCytokineticsN/APRAXPraxis Precision Medicines67.84%RLAYRelay Therapeutics96.98%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/ACYTKCytokinetics2.60%PRAXPraxis Precision Medicines2.70%RLAYRelay Therapeutics5.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6179.69 millionN/ANot OptionableCYTKCytokinetics250124.43 million121.20 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.13 millionOptionableRLAYRelay Therapeutics330191.59 million181.93 millionOptionableRLAY, ABVX, PRAX, and CYTK HeadlinesRecent News About These CompaniesRelay Therapeutics Target of Unusually High Options Trading (NASDAQ:RLAY)June 4 at 4:36 AM | americanbankingnews.comContrasting Miravant Medical Technologies (OTCMKTS:MRVT) & Relay Therapeutics (NASDAQ:RLAY)June 3 at 7:05 AM | americanbankingnews.comRelay Therapeutics to Participate in Two Upcoming Investor Conferences in JuneMay 27, 2026 | globenewswire.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Buy" from AnalystsMay 26, 2026 | americanbankingnews.comRelay Therapeutics, Inc. (RLAY) Presents at ISSVA World Congress 2026: The Latest in Vascular Anomalies - SlideshowMay 22, 2026 | seekingalpha.comRelay Therapeutics (RLAY) Is Up 6.9% After Follow-On Offering And Early Zovegalisib Data ReleaseMay 22, 2026 | finance.yahoo.comRelay Therapeutics prices $275M public offering of common stock at $12/shareMay 21, 2026 | msn.comRelay Therapeutics: Encouraging Data, Competitive Risks (Downgrade)May 21, 2026 | seekingalpha.comJonesTrading Upgrades Relay Therapeutics (NASDAQ:RLAY) to Strong-BuyMay 21, 2026 | marketbeat.comRLAY stock declines pre-market after $175M offering — despite fresh bullish calls on Relay's zovegalisibMay 21, 2026 | msn.comRelay Therapeutics Prices Underwritten Public Offering of Common Stock Raising Approximately $275 MillionMay 20, 2026 | quiverquant.comQRelay Therapeutics Announces Pricing of Public Offering of Common StockMay 20, 2026 | globenewswire.comWhy Relay Therapeutics Stock Popped on WednesdayMay 20, 2026 | fool.comRelay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies - SlideshowMay 20, 2026 | seekingalpha.comRelay Therapeutics (NASDAQ:RLAY) Trading 10.9% Higher After Analyst UpgradeMay 20, 2026 | marketbeat.comRelay Therapeutics Sees Unusually Large Options Volume (NASDAQ:RLAY)May 20, 2026 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Given New $21.00 Price Target at Citizens JmpMay 20, 2026 | marketbeat.comRelay Therapeutics: Zovegalisib Is Becoming A Platform In DisguiseMay 20, 2026 | seekingalpha.comRelay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies TranscriptMay 19, 2026 | seekingalpha.comRelay Therapeutics Announces Proposed Public Offering of Common StockMay 19, 2026 | globenewswire.comRelay Therapeutics stock surges on vascular anomalies trial dataMay 19, 2026 | au.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRLAY, ABVX, PRAX, and CYTK Company DescriptionsAbivax NASDAQ:ABVX$101.53 -3.40 (-3.24%) Closing price 04:00 PM EasternExtended Trading$100.75 -0.78 (-0.77%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Cytokinetics NASDAQ:CYTK$71.48 -0.81 (-1.12%) Closing price 04:00 PM EasternExtended Trading$71.32 -0.17 (-0.23%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Praxis Precision Medicines NASDAQ:PRAX$254.00 -10.75 (-4.06%) Closing price 04:00 PM EasternExtended Trading$249.52 -4.47 (-1.76%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Relay Therapeutics NASDAQ:RLAY$13.52 -1.02 (-7.02%) Closing price 04:00 PM EasternExtended Trading$13.23 -0.29 (-2.14%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
